Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma

Phase 1 Completed 65 enrolled Duke University National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with temozolomide may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate when given together with temozolomide in treating patients with malignant glioma.

Timeline

Start: 2004-07
Primary completion: 2008-11
Completion: 2008-11

Publications

Results Reardon DA, Desjardins A, Vredenburgh JJ, Sathornsumetee S, Rich JN, Quinn JA, Lagattuta TF, Egorin MJ, Gururangan S, McLendon R, Herndon JE 2nd, Friedman AH, Salvado AJ, Friedman HS. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol. 2008 Jun;10(3):330-40. doi: 10.1215/15228517-2008-003. Epub 2008 Mar 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imatinib	Small molecule	400 mg	Oral
Subject	Imatinib	Small molecule	1200 mg	Oral
Subject	Temozolomide	Small molecule	150 mg/m2	—
Subject	Temozolomide	Small molecule	200 mg/m2	—

Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma

Summary

Timeline

Publications

Drugs

Indications